These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 18394773)

  • 41. Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor.
    Shibuya M
    FEBS J; 2009 Sep; 276(17):4636-43. PubMed ID: 19664071
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pyruvate kinase isoenzyme M2 is not of diagnostic relevance as a marker for oral cancer.
    Ervens J; Fuchs H; Niemann VT; Hoffmeister B
    J Craniomaxillofac Surg; 2008 Mar; 36(2):89-94. PubMed ID: 18243718
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer.
    Carrillo de Santa Pau E; Arias FC; Caso Peláez E; Muñoz Molina GM; Sánchez Hernández I; Muguruza Trueba I; Moreno Balsalobre R; Sacristán López S; Gómez Pinillos A; del Val Toledo Lobo M
    Cancer; 2009 Apr; 115(8):1701-12. PubMed ID: 19197998
    [TBL] [Abstract][Full Text] [Related]  

  • 44. NF-KappaB expression correlates with apoptosis and angiogenesis in clear cell renal cell carcinoma tissues.
    Meteoglu I; Erdogdu IH; Meydan N; Erkus M; Barutca S
    J Exp Clin Cancer Res; 2008 Oct; 27(1):53. PubMed ID: 18928570
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pyruvate kinase isoenzyme M2 is a glycolytic sensor differentially regulating cell proliferation, cell size and apoptotic cell death dependent on glucose supply.
    Spoden GA; Rostek U; Lechner S; Mitterberger M; Mazurek S; Zwerschke W
    Exp Cell Res; 2009 Oct; 315(16):2765-74. PubMed ID: 19563799
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunohistochemical evaluation of the tumor neoangiogenesis as a prognostic factor for gastric cancers.
    Lazăr D; Tăban S; Raica M; Sporea I; Cornianu M; Goldiş A; Vernic C
    Rom J Morphol Embryol; 2008; 49(2):137-48. PubMed ID: 18516318
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Glycolytic phenotype in breast cancer: activation of Akt, up-regulation of GLUT1, TKTL1 and down-regulation of M2PK.
    Schmidt M; Voelker HU; Kapp M; Krockenberger M; Dietl J; Kammerer U
    J Cancer Res Clin Oncol; 2010 Feb; 136(2):219-25. PubMed ID: 19655166
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study.
    Schilder RJ; Sill MW; Lee RB; Shaw TJ; Senterman MK; Klein-Szanto AJ; Miner Z; Vanderhyden BC
    J Clin Oncol; 2008 Jul; 26(20):3418-25. PubMed ID: 18612157
    [TBL] [Abstract][Full Text] [Related]  

  • 49. No activating mutations of FSH receptor in four children with ovarian juvenile granulosa cell tumors and the association of these tumors with central precocious puberty.
    Bas F; Pescovitz OH; Steinmetz R
    J Pediatr Adolesc Gynecol; 2009 Jun; 22(3):173-9. PubMed ID: 19539204
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Transketolase protein TKTL1 overexpression: A potential biomarker and therapeutic target in breast cancer.
    Földi M; Stickeler E; Bau L; Kretz O; Watermann D; Gitsch G; Kayser G; Zur Hausen A; Coy JF
    Oncol Rep; 2007 Apr; 17(4):841-5. PubMed ID: 17342325
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The role of vascular endothelial growth factors and their receptors in malignant melanomas.
    Brychtova S; Bezdekova M; Brychta T; Tichy M
    Neoplasma; 2008; 55(4):273-9. PubMed ID: 18505336
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tumor-specific pyruvate kinase isoenzyme M2 involved in biochemical strategy of energy generation in neoplastic cells.
    Gumińska M; Ignacak J; Kedryna T; Stachurska MB
    Acta Biochim Pol; 1997; 44(4):711-24. PubMed ID: 9584851
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
    Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
    J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Expression of PC cell-derived growth factor and vascular endothelial growth factor in esophageal squamous cell carcinoma and their clinicopathologic significance.
    Chen XY; Li JS; Liang QP; He DZ; Zhao J
    Chin Med J (Engl); 2008 May; 121(10):881-6. PubMed ID: 18706200
    [TBL] [Abstract][Full Text] [Related]  

  • 55. siRNA targeting VEGF inhibits hepatocellular carcinoma growth and tumor angiogenesis in vivo.
    Raskopf E; Vogt A; Sauerbruch T; Schmitz V
    J Hepatol; 2008 Dec; 49(6):977-84. PubMed ID: 18845354
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunohistochemical expression of the cyclooxygenase-2 (COX-2) in gastric cancer. The correlations with the tumor angiogenesis and patients' survival.
    Lazăr D; Tăban S; Ardeleanu C; Simionescu C; Sporea I; Cornianu M; Vernic C
    Rom J Morphol Embryol; 2008; 49(3):371-9. PubMed ID: 18758643
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Visfatin activates eNOS via Akt and MAP kinases and improves endothelial cell function and angiogenesis in vitro and in vivo: translational implications for atherosclerosis.
    Lovren F; Pan Y; Shukla PC; Quan A; Teoh H; Szmitko PE; Peterson MD; Gupta M; Al-Omran M; Verma S
    Am J Physiol Endocrinol Metab; 2009 Jun; 296(6):E1440-9. PubMed ID: 19351806
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Granulosa cell tumors of the ovary with a pseudopapillary pattern: a study of 14 cases of an unusual morphologic variant emphasizing their distinction from transitional cell neoplasms and other papillary ovarian tumors.
    Irving JA; Young RH
    Am J Surg Pathol; 2008 Apr; 32(4):581-6. PubMed ID: 18301054
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Is Her-2/neu expressed in nonepithelial ovarian malignancies?
    Menczer J; Schreiber L; Czernobilsky B; Berger E; Golan A; Levy T
    Am J Obstet Gynecol; 2007 Jan; 196(1):79.e1-4. PubMed ID: 17240244
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The relevance of angiogenesis in benign and malignant epithelial tumors of the ovary: a quantitative histologic study.
    Brustmann H; Riss P; Naudé S
    Gynecol Oncol; 1997 Oct; 67(1):20-6. PubMed ID: 9345351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.